Nano-based carriers for pulmonary drug delivery: A review on the available drug delivery applications and toxicity issues

Basit Öğe Kaydı
dc.authoridÜstündağ Okur, Neslihan/0000-0002-3210-3747
dc.authorwosidÜstündağ Okur, Neslihan/AAI-1863-2019
dc.contributor.authorSiafaka, Panoraia I.
dc.contributor.authorBulbul, Ece Ozcan
dc.contributor.authorMiliotou, Androulla N.
dc.contributor.authorKarantas, Ioannis D.
dc.contributor.authorOkur, Mehmet Evren
dc.contributor.authorOkur, Neslihan Ustundag
dc.date.accessioned2024-05-19T14:45:57Z
dc.date.available2024-05-19T14:45:57Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractIn the last decade, nanocarriers have been widely used to target specific organs and disorders of any kind. Nonetheless, the commercialization of nanocarriers for many disorders have not been finalized; toxicity matters, materials which have not granted approval by regular authorities, or unavailability of clinical studies are some of the issues which the researchers should overcome to force the marketing of nanoparticles. Pulmonary diseases affect million people worldwide, in example, pulmonary infections, malignancies, asthma and chronic obstructive pulmonary disease are among the most frequent. It has been reported that the local administration of drugs to lungs via inhalers can solve the most side effects arouse by per os or intravenous delivery. Therefore, in this review the current state of drug delivery nanosized carriers which can be applied via inhalation are discussed and analyzed. Moreover, the possible toxicity issues due to their small size or materials used for the preparation of such nanocarriers are being discussed. It was performed a thorough literature research based on databases as PubMed (R) and ScienceDirect (R) by using nanocarriers, pulmonary, lung disorders, inhalation, toxicity as keywords. According to our inclusion criteria, studies including the previous terms, focusing on nanoparticles that can be applied for lung disorders management, were added. From our point of view, this bibliographic analysis can enhance the present knowledge of researchers for inhalable nanostructures, targeting pulmonary diseases.en_US
dc.identifier.doi10.1016/j.jddst.2024.105381
dc.identifier.issn1773-2247
dc.identifier.issn2588-8943
dc.identifier.scopus2-s2.0-85183555932en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1016/j.jddst.2024.105381
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5399
dc.identifier.volume92en_US
dc.identifier.wosWOS:001170757600001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Drug Delivery Science and Technologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectNanocarriersen_US
dc.subjectPulmonaryen_US
dc.subjectRespiratoryen_US
dc.subjectLung Disordersen_US
dc.subjectInhalationen_US
dc.subjectInhalersen_US
dc.titleNano-based carriers for pulmonary drug delivery: A review on the available drug delivery applications and toxicity issuesen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu